{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:21:37Z","timestamp":1794932497979,"version":"4.9.1"},"reference-count":0,"publisher":"BioExcel","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"DOI":"10.7573\/dic.2023-12-5","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T11:51:35Z","timestamp":1710417095000},"page":"1-10","source":"Crossref","is-referenced-by-count":6,"title":["Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study"],"prefix":"10.7573","volume":"13","author":[{"given":"Tiago","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mendes Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Magina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martinha","family":"Henrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2024,3,18]]},"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2024\/03\/dic.2023-12-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T11:51:36Z","timestamp":1710417096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-a-52-week-real-world-portuguese-multicentric-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":0,"URL":"https:\/\/doi.org\/10.7573\/dic.2023-12-5","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}